| An epidemic rise in
one under-publicized category of cancers should sound an alarm for
all Americans. There is a worrying coincidence associated with the
dramatic surge in lymphatic cancer: Before 1995, lymphatic cancers
were comparatively rare. In 1994 genetically engineered bovine growth
hormone (rbGH) was approved for use by the FDA. Today, if one adds
up the total number of cancer deaths from breast, prostate, lung,
pancreatic, and genital cancers, they do not cumulatively equal the
number of deaths from lymphatic cancers. Do I have your attention?
This year Americans will consume nearly 180 billion pounds of milk
and dairy products in various forms. That will average out to 666
pounds per American, nearly 40% of the average American diet. Cheese
eaters, ice cream slurpers, and milk drinkers of both sexes and
every age group will be ingesting dairy products from hormonally-treated
cows. Most Americans are unaware that laboratory animals treated
with rbGH experienced enormous changes in their lymphatic systems.
The spleens of these animals grew dramatically.
The controversial genetically modified cow hormone was approved
for human consumption in February of 1994. Cancer statistics have
recently been published by the U.S. Census Bureau comparing death
rates from cancer by sex and age groups in 1980, 1990, and 1995.
These data support evidence of a runaway plague. All of America
became a laboratory study for rbGH, which is now in America's ice
cream, cheese, and pizza.
There are small increases and decreases in lymphatic cancer rates
from 1980 to 1990, depending upon sex and age group. What happened
in 1995 represents the most dramatic short-term increase of any
single cancer in the history of epidemiological discovery and analyses.
DEATH RATES FROM LYMPHATIC CANCER BY SEX AND AGE
(1980 - 1995)
(Deaths per 100,000 population
in specified age group)
|
MALE
|
FEMALE |
|
%
|
% |
|
1980 1990 1995 increase
|
1980 1990 1995 increase
|
|
AGE GROUPS
|
|
|
35-44 4.3 4.5 36.5 811%
|
2.4 2.1 44.0
2095% |
|
45-54 10.2 10.9 143.7 1318%
|
6.6 6.0 140.7 2345% |
|
55-64 24.4 27.2 480.5 1767%
|
16.8 16.7 357.5 2141% |
|
65-74 48.1 56.8 1089.9 1919%
|
34.4 39.5 690.7 1749% |
|
75-84 80.0 104.5 1842.3 1763%
|
57.6 71.2 1061.5 1495% |
|
85+ 93.2 140.5 2837.3 2019%
|
63.0 90.0 1249.1 1588% |
The approval process for rbGH was the most controversial drug application
in the history of the Food & Drug Administration (FDA). In
order to address that controversy, the FDA published an article
in the journal SCIENCE (August 24, 1990).
Data in that paper reveal that the average male rat receiving rbGH
developed a spleen 39.6 percent larger than the spleen of the control
animals after just 90 days of treatment. The spleens from rbGH-treated
females increased in size by a factor of 46 percent. These are not
normal reactions and portray animals in distress. These animals
were "under attack" by the genetically engineered hormone.
The spleen is the first line of defense in a mammal's lymphatic
system.
Lab animals treated with rbGH developed lymphatic abnormalities.
This same hormone causing changes in lab animals was introduced
into America's food supply in 1994. As Americans continue to ingest
genetically engineered milk and dairy products, lymphatic cancer
rates soar. Americans have become laboratory subjects in genetic
engineering's experiment, and the resulting data indicate extreme
cause for concern.
Robert Cohen is the Executive Director of the Dairy Education
Board. For more information visit their website - http://www.notmilk.com.
|
